FDA and CDC expand approval of updated Moderna and Pfizer-BioNTech COVID-19 booster vaccines for children Ages 5-17
Author
Blaire Bryant
Upcoming Events
Related News
Key Takeaways
On October 12, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 vaccines for children ages 5-17. Under the amended EUA, the Moderna vaccine is authorized for children ages 6 through 17 years of age, and the Pfizer vaccine is authorized for children five to 11 years of age.
Following FDA authorization, the Centers for Disease Control and Prevention (CDC), updated their COVID-19 vaccination recommendations to include the boosters for this younger age group.
Updated COVID-19 boosters add Omicron BA.4 and BA.5 variants to the current vaccine composition, helping to restore protection that has waned since previous vaccination and targeting recent Omicron strains that are more transmissible and immune compromising.
The approval of the updated COVID-19 boosters is a critical next step in the nation’s pandemic recovery efforts. County governments have been on the front lines of our nation’s vaccination efforts and will continue to work to coordinate distribution and administration of vaccines, which provide increased protection against severe COVID-19 disease and mortality.
ADDITIONAL RESOURCES
Resource
The County Role in Vaccines
Related News
U.S. House reintroduces legislation to address the Medicaid Inmate Exclusion Policy with NACo support
Two bipartisan bills aimed at addressing the Medicaid Inmate Exclusion Policy (MIEP) were recently reintroduced in the U.S. House of Representatives.
U.S. House of Representatives re-establishes Bipartisan Mental Health Caucus with NACo support
On May 7, members of the U.S. House of Representatives appointed new leadership to the Bipartisan Mental Health Caucus, reaffirming their commitment to addressing the nation’s mental health crisis through cross-party collaboration.
House passes SUPPORT Act reauthorization
On June 4, the U.S. House of Representatives passed the SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483) by a strong bipartisan vote of 366–57. The bill, which reauthorizes billions of dollars for critical programs that target overdose prevention, now heads to the Senate Committee on Health, Education, Labor and Pensions, where a version of the bill was overwhelmingly advanced with bipartisan support in the 118th Congress.